Send to

Choose Destination
Obstet Gynecol Clin North Am. 2007 Dec;34(4):761-81, ix.

Prophylactic human papillomavirus vaccination: a breakthrough in primary cervical cancer prevention.

Author information

Obstetrics and Gynecology, Public Health and Mexican-American Studies, National Center of Excellence in Women's Health, The University of Arizona, University Medical Center, 1501 North Campbell Avenue, Tucson, AZ 85724, USA.


Nearly all cervical cancers require human papillomavirus infection (HPV) for subsequent carcinogenesis. The identification of this obligate viral etiology, in addition to a vast knowledge about the HPV viral life cycle and resultant host response, has led to a vaccine approach to cervical cancer prevention. The use of prophylactic cancer vaccine as primary prevention holds the most promise for long-term cancer prevention but raises some important and as yet unanswered questions that are addressed in this article.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center